tetano
Editor, Senior Moderator
Clin Infect Dis. 2020 May 8. pii: ciaa547. doi: 10.1093/cid/ciaa547. [Epub ahead of print]
Lessons from COVID-19 in children: Key hypotheses to guide preventative and therapeutic strategies.
Singh T[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Heston SM[SUP]4[/SUP], Langel SN[SUP]1,[/SUP][SUP]4[/SUP], Blasi M[SUP]1,[/SUP][SUP]5[/SUP], Hurst JH[SUP]4,[/SUP][SUP]3[/SUP], Fouda GG[SUP]1,[/SUP][SUP]2,[/SUP][SUP]4[/SUP], Kelly MS[SUP]4[/SUP], Permar SR[SUP]1,[/SUP][SUP]2,[/SUP][SUP]4,[/SUP][SUP]3[/SUP].
Author information
Abstract
The current pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), reveals a peculiar trend of milder disease and lower case fatality in children compared to adults. Consistent epidemiologic evidence of reduced severity of infection in children across different populations and countries suggests there are underlying biologic differences between children and adults that mediate differential disease pathogenesis. This presents a unique opportunity to learn about disease modifying host factors from pediatric populations. Our review summarizes the current knowledge of pediatric clinical disease, role in transmission, risks for severe disease, protective immunity, as well as novel therapies and vaccine trials for children. We then define key hypotheses and areas for future research that can use the pediatric model of disease, transmission, and immunity to develop preventive and therapeutic strategies for people of all age groups.
? The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
KEYWORDS:
COVID-19; Children; Pediatrics; SARS-CoV-2; Vaccines
PMID:32382748DOI:10.1093/cid/ciaa547
Lessons from COVID-19 in children: Key hypotheses to guide preventative and therapeutic strategies.
Singh T[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Heston SM[SUP]4[/SUP], Langel SN[SUP]1,[/SUP][SUP]4[/SUP], Blasi M[SUP]1,[/SUP][SUP]5[/SUP], Hurst JH[SUP]4,[/SUP][SUP]3[/SUP], Fouda GG[SUP]1,[/SUP][SUP]2,[/SUP][SUP]4[/SUP], Kelly MS[SUP]4[/SUP], Permar SR[SUP]1,[/SUP][SUP]2,[/SUP][SUP]4,[/SUP][SUP]3[/SUP].
Author information
Abstract
The current pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), reveals a peculiar trend of milder disease and lower case fatality in children compared to adults. Consistent epidemiologic evidence of reduced severity of infection in children across different populations and countries suggests there are underlying biologic differences between children and adults that mediate differential disease pathogenesis. This presents a unique opportunity to learn about disease modifying host factors from pediatric populations. Our review summarizes the current knowledge of pediatric clinical disease, role in transmission, risks for severe disease, protective immunity, as well as novel therapies and vaccine trials for children. We then define key hypotheses and areas for future research that can use the pediatric model of disease, transmission, and immunity to develop preventive and therapeutic strategies for people of all age groups.
? The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
KEYWORDS:
COVID-19; Children; Pediatrics; SARS-CoV-2; Vaccines
PMID:32382748DOI:10.1093/cid/ciaa547